Literature DB >> 2300980

Cyclosporine A reduces cerebral vasospasm after subarachnoid hemorrhage in dogs.

J W Peterson1, S Nishizawa, J D Hackett, T Bun, A Teramura, N T Zervas.   

Abstract

The double subarachnoid hemorrhage canine model was used to test the prophylactic value of immunosuppression in the prevention of cerebral vasospasm after subarachnoid hemorrhage. Dogs treated with cyclosporine A following the regimen prescribed for organ transplant procedures in patients showed a significant reduction in the severity of angiographic constriction of cerebral arteries. While basilar artery diameter after double experimental subarachnoid hemorrhage in a series of untreated dogs (n = 34) averaged 65% of baseline diameter, arterial diameter in dogs treated prophylactically (n = 18) with 6 mg/kg/day cyclosporine A and adjunct low-dose steroid averaged 80% of baseline diameter, for a mean reduction in the severity of chronic arterial constriction of 42%. More important than the average effect, however, is the statistical observation that this mean improvement was obtained primarily by a dramatic reduction in the incidence of severe cerebral vasospasm, the situation most likely to account for morbidity and mortality after aneurysmal rupture.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300980     DOI: 10.1161/01.str.21.1.133

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

1.  HLA antigens and intracranial aneurysms.

Authors:  M Ryba; P Grieb; I Podobińska; K Iwańska; M Pastuszko; A Górski
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

2.  Endovascular treatment using low-power ultraviolet laser for delayed vasospasm in the rabbit carotid artery model.

Authors:  Kanji Nakai; Yuji Numaguchi; Thomas H Foster; Katsuji Shima; Makoto Kikuchi
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

3.  Expression of intercellular adhesion molecule 1 (ICAM-1) on the cerebral artery following subarachnoid haemorrhage in rats.

Authors:  Y Handa; T Kubota; M Kaneko; A Tsuchida; H Kobayashi; H Kawano; T Kubota
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

4.  2-Chloro-2' deoxyadenosine prevents angiopathic changes in cerebral arteries in experimental SAH in rabbits.

Authors:  M Ryba; P Grieb; M Walski; J Sawicki; M Pastuszko
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

5.  Is vascular angiopathy following intracranial aneurysm rupture immunologically mediated?

Authors:  M Ryba; M Jarzabek-Chorzelska; T Chorzelski; M Pastuszko
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Cyclosporine A prevents neurological deterioration of patients with SAH--a preliminary report.

Authors:  M Ryba; M Pastuszko; K Iwanska; J Bidzinski; C Dziewiecki
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

8.  The effect of immunosuppression on the development of cerebral oedema in an experimental model of intracerebral haemorrhage: whole body and regional irradiation.

Authors:  P J Kane; P Modha; R D Strachan; S Cook; I R Chambers; C B Clayton; A D Mendelow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

9.  Morphometric and ultrastructural analysis of the effect of bromocriptine and cyclosporine on the vasospastic femoral artery of rats.

Authors:  Mehmet Tokmak; Kahan Başocak; Hüseyin Canaz; Gökhan Canaz; Celal İplikçioğlu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  A strategy for analyzing multiple parameters with application to aneurysmal SAH patients all of them clipped but treated with and without cyclosporine.

Authors:  M Ryba; M Pastuszko; C Dziewiecki; J Andrychowski; P Bojarski; M Barczewska
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.